Clinical Trial

FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom

Study acronym: FECD-TRACE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
FECD-TRACE is an integral component of a large research program dedicated to Fuchs Endothelial Corneal Dystrophy (FECD) in the United Kingdom. This longitudinal, observational study aims to comprehensively characterize a cohort of younger research participants who have a genetic predisposition to developing FECD. By utilizing advanced anterior segment imaging techniques, the study will monitor these individuals over a span of several years, capturing phenotypic changes that reflect the progression of the disease. Concurrently, genetic biomarkers will be examined to establish correlations with the observed phenotypic changes. The primary objective of FECD-TRACE is to enhance our understanding of the intricate genetic mechanisms underlying FECD and establish connections between these genetic findings and clinical outcomes. Ultimately, this research strives to facilitate the development of personalized care approaches for individuals affected by FECD.
Trial Details
NCT Number NCT06881771
Lead Sponsor University College, London
Conditions Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Fuchs' Endothelial Corneal Dystrophy of Bilateral Eyes, Corneal Dystrophy Fuchs, Corneal Dystrophy
Enrollment 500 participants
Start Date 2024-02-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-18